Nonsquamous Non-small Cell Lung Cancer
Oncology
4
Pipeline Programs
3
Companies
1
Clinical Trials
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
1
0
0
3
0
Early DiscoveryClinical DevelopmentMarket
Drug Modality Breakdown
Monoclonal Antibody
267%
ADC
133%
+ 1 programs with unclassified modality
Competitive Landscape
3 companies ranked by most advanced pipeline stage
Trial Timeline
Clinical trial activity over time
2023
2024
2025
2026
XencorVudalimab + Carboplatin + Pemetrexed
Clinical Trials (1)
Total enrollment: 28 patients across 1 trials
Study of Vudalimab or Pembrolizumab in Combination With Chemotherapy as First-line Treatment in Patients With Advanced NSCLC
Start: Dec 2023Est. completion: Dec 202528 patients
Phase 1/2Terminated
Related Jobs in Oncology
Summer intern Neuroscience
Arvinas
New Haven - CT
6h ago
Medical Representative - CVRM - HCM
AstraZeneca
Vietnam - Ho Chi Minh City
11h ago
Operator
Sartorius Stedim Biotech
Shanghai
11h ago
Technician, Quality Assurance - Night Shift
Orca Bio
Sacramento, CA
11h ago
$65K - $71K/yr
Supervisor, Materials and Cold Chain Operations - Night Shift
Orca Bio
Sacramento, CA
17h ago
$75K - $95K/yr
Supervisor, Materials and Cold Chain Operations - Day Shift
Orca Bio
Sacramento, CA
17h ago
$75K - $95K/yr
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
3 late-stage (Phase 3) programs — potential near-term approvals
Monoclonal Antibody is the dominant modality (67% of programs)
3 companies competing in this space